[F1SCHEDULE 1

Regulation 4(1)

Fees

Textual Amendments

F1 Sch. 1 substituted (6.4.2016) by The Plant Protection Products (Fees and Charges) (Amendment) Regulations 2016 (S.I. 2016/254), regs. 1, **2(2)**

Fees for application and evaluation of a plant protection product for authorisation

1. Fees for product-related applications **[**F2to a United Kingdom competent authority**]** are in accordance with the following table, and each item is charged cumulatively.

Item	*Chargeable item*	*Fee(£)*
1	Administrative research and development application(1)	52
2	Extension of use application including administration, co-ordination and technical consideration	1,768
3	Preliminary consideration of application type listed in items 4, 5, 7,12 or 13 to determine whether the application can proceed further	229
4	Administrative application(2)	
	F3 … for a new product or change to an existing product—	
4a	one product	156
4b	each additional product(4)	52
5	F4 . . .	
5a	F4 . . .	F4 . . .
5b	F4 . . .	F4 . . .
6	Evaluation of a label in any application	208
7	Co-ordination of standard technical stream applications (7)(8)	1,872
8	Evaluation of simple reasoned cases in each of the following specialist areas—	
8a	chemistry(9)	416
8b	toxicology(10)	416
8c	operator exposure(11)	416
8d	residues and consumer exposure(12)	416
8e	fate and behaviour in the environment(13)	416

Item	*Chargeable item*	*Fee(£)*
8f	ecotoxicology(14)	416
8g	efficacy(15)	416
9	Evaluation of data, modelling and detailed scientific cases in each of the following specialist areas—	
9a	chemistry(9)	780
9b	toxicology(10)	780
9c	operator exposure(11)	780
9d	residues and consumer exposure(12)	780
9e	fate and behaviour in the environment(13)	1,872
9f	ecotoxicology(14)	1,872
9g	efficacy(15)	1,872
10	Withdrawal of an application for a product specified in items 2, 4, 5, 7, 12 or 13 before any work other than preliminary consideration has been done	104
11	Pre-submission meetings **[**F5to discuss potential product applications**]**(16)	5,200
12	F6	
	. . .	
	F6	F6
	. . .	. . .
	F6	F6
	. . .	. . .
13	Commenting on draft study protocols(18)	416

Notes

(1) Application for authorisation under Regulation 1107/2009 not involving evaluation of technical information or data.

(2) Application for authorisation under Regulation 1107/2009 involving no technical consideration.

F7(3) . . . . . .

(4) Where the application relates to a number of different products, this charge applies to each additional product.

F7(5) . . . . . .

F7(6) . . . . . .

(7) "Standard technical stream applications" are all applications other than **[**F8items 1-4, 10 and 11**]**.

(8) The co-ordination of applications for new products or a change to an existing product.

(9) Chemistry covers assessment of the technical specification of the active substance, safeners and synergists in the product and the physico-chemical properties of the product.

(10) Toxicology covers assessment of the mammalian metabolism and toxicology of the active substance, safeners and synergists in the product and determination of the types of hazard to which the product can give rise.

(11) Operator exposure additionally covers exposure of other persons resulting from the product use.

(12) Consumer exposure covers exposure of consumers resulting from consumption of produce from treated crops, treated produce or products derived from either, including products from animals to which any such matter has been fed.

(13) Fate and behaviour in the environment covers the potential environmental exposure from product use, including the identity and quantity of the active substance, metabolites, degradation products and reaction products, safeners and synergists which may be available in the soil, water or air and are of toxicological or environmental significance.

(14) Ecotoxicology covers the assessment of the potential impact on non-target species likely to be at risk from exposure to the product, including the active substance, and toxicologically or environmentally significant metabolites, degradation products and reaction products, safeners and synergists.

(15) Efficacy covers the assessment of whether a product consistently controls the target pest and whether the product adversely affects the treated crops, following crops or treated produce.

(16) Pre-submission meetings may be held at the request of the applicant prior to the submission of an application [F9]....

[F10](17) . . . . . .

(18) The fee is equivalent to a specialist case fee and relates to requests from applicants for **[**[F11]a United Kingdom competent authority**]** to comment on the study design in advance of the data being generated and an application being submitted. For particularly complex protocols requiring significant specialist input it may be necessary to charge a data module fee in the relevant specialist area.

Textual Amendments

F2 Words in Sch. 1 para. 1 inserted (31.12.2020) by S.I. 2019/720, **Sch. 1 para. 14(2)(a)** (as inserted by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), **Sch. 1 para. 10(2)(b)**)

F3 Word in Sch. 1 para. 1 Table Item 4 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(2)(b)(i)** (as amended by S.I. 2020/1567, reg. 1(2), **Sch. 1 para. 10(2)(a)**); 2020 c. 1, **Sch. 5 para. 1(1)**

F4 Sch. 1 para. 1 Table Item 5-5b omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(2)(b)(ii)** (as amended by S.I. 2020/1567, reg. 1(2), **Sch. 1 para. 10(2)(a)**); 2020 c. 1, **Sch. 5 para. 1(1)**

F5 Words in Sch. 1 para. 1 Table Item 11 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(2)(b)(iii)** (as amended by S.I. 2020/1567, reg. 1(2), **Sch. 1 para. 10(2)(a)**); 2020 c. 1, **Sch. 5 para. 1(1)**

F6 Words in Sch. 1 para. 1 Table Item 12 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations

2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(2)(b)(iv)** (as amended by S.I. 2020/1567, reg. 1(2), **Sch. 1 para. 10(2)(a)**); 2020 c. 1, **Sch. 5 para. 1(1)**

F7 Sch. 1 para. 1 Notes 3, 5, 6 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(2)(c)(i)** (as amended by S.I. 2020/1567, reg. 1(2), **Sch. 1 para. 10(2)(a)**); 2020 c. 1, **Sch. 5 para. 1(1)**

F8 Words in Sch. 1 para. 1 Note 7 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(2)(c)(ii)** (as amended by S.I. 2020/1567, reg. 1(2), **Sch. 1 para. 10(2)(a)**); 2020 c. 1, **Sch. 5 para. 1(1)**

F9 Words in Sch. 1 para. 1 Note 16 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(2)(c)(iii)** (as amended by S.I. 2020/1567, reg. 1(2), **Sch. 1 para. 10(2)(a)**); 2020 c. 1, **Sch. 5 para. 1(1)**

F10 Sch. 1 para. 1 Note 17 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(2)(c)(iv)** (as amended by S.I. 2020/1567, reg. 1(2), **Sch. 1 para. 10(2)(a)**); 2020 c. 1, **Sch. 5 para. 1(1)**

F11 Words in Sch. 1 para. 1 Note 18 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(2)(c)(v)** (as amended by S.I. 2020/1567, reg. 1(2), **Sch. 1 para. 10(2)(a)**); 2020 c. 1, **Sch. 5 para. 1(1)**

[F12 1A. Fees for parallel trade applications to the Northern Ireland competent authority are in accordance with the following table, and each item is charged cumulatively.

Item	*Chargeable item*	*Fee(£)*
1	Preliminary consideration of an application to determine whether the application can proceed further	229
2	Parallel trade applications—	
	(a) co-ordination of application for a new product or change to an existing product involving parallel trade(1)	728
	(b) parallel trade verification(2)	208
	(c) parallel trade permit for personal use	156

(1) Application for a parallel trade permit for other than personal use.

(2) Verification that the product to be traded is identical to a product authorised in accordance with Regulation 1107/2009.**]**

Textual Amendments

F12 Sch. 1 para. 1A inserted (31.12.2020) by S.I. 2019/720, **Sch. 01 para. 014(02A)** (as inserted by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), **Sch. 1 para. 10(3)**)

Fees for application and evaluation of an active substance, safener [F13, synergist or basic substance]

2. The fees **[**F14chargeable by a Great Britain competent authority**]** for evaluation for approval, or renewal of approval, under Regulation 1107/2009 of an active substance, safener **[**F15, synergist or basic substance**]**, are in accordance with the following table.

Item	*Application*	*Fee(£)*
	Where an active substance, safener [F16, synergist or basic substance] is neither a biocontrol agent nor a pheromone	
1	Preliminary evaluation(1) of the admissibility of an application	5,200
2	F17	F17
	. . .	. . .
3	**[**F18Co-ordination of scientific advice and public consultation and finalising the draft assessment report**]**	36,400
4	Evaluation of a full data package(3)	114,400
5	Evaluation of a partial data package(4):	
	Band 1	7,800
	Band 2	15,600
	Band 3	31,200
	Band 4	52,000
	Band 5	72,800
	Band 6	93,600
	Band 7	114,400
	Where an active substance is a biocontrol agent	
6	Evaluation of a full data package (3)	23,400
7	**[**F19Co-ordination of scientific advice and public consultation, and finalising the draft assessment report**]**	7,800
8	Evaluation of a partial data package(4):	
	Band 1	5,720
	Band 2	11,700
	Band 3	17,680
	Band 4	23,400
	Where an active substance is a pheromone	
9	Evaluation of a full data package(3)	13,520
10	**[**F19Co-ordination of scientific advice and public consultation, and finalising the draft assessment report**]**	7,800

Item	*Application*	*Fee(£)*
11	Evaluation of a partial data package:(4)	
	Band 1	3,380
	Band 2	6,760
	Band 3	10,140
	Band 4	13,520
	For all evaluations	
12	Meeting before the submission of an application in support of a new active substance, safener, synergist, **[**F20basic substance,**]** biocontrol agent or pheromone	5,200

Notes

(1) The initial evaluation carried out in order to notify the applicant whether his or her application can proceed further.

F21(2) . . . . . .

(3) **[**F22In relation to active substances, safeners or synergists,**]** a full data package comprises the complete dossier (the information referred to in paragraphs 1 and 2 of Article 8 of Regulation 1107/2009) to support one or more representative use of one product. **[**F23In relation to basic substances, a full data package comprises the complete dossier (the information referred to in Article 23(3) of Regulation 1107/2009) to support one or more uses of the basic substance.**]** Where a data package also contains a large number of extra study reports submitted to refine risk assessments, to characterise metabolites or to support additional uses of the product **[**F24or basic substance**]**, these studies will be treated as an additional partial data package. See also note (4).

(4) The size of a partial data package is banded as a proportion of a full data package. The proportion is estimated on the basis of the amount of time required to evaluate the data and to conduct the necessary risk assessments. Applicants will be notified of the appropriate Band prior to an evaluation taking place. Partial data packages include one or more of the following—

(a) additional data over and above a 'standard' core dossier for example situations where there are significantly more metabolites, or very large novel studies to be evaluated;

(b) additional study submissions during evaluation required to clarify the initial dossier;

F25(c) . . . . . .

(d) **[**F26 in relation to active substances, safeners or synergists,**]** data to support the extension of the approval of an active substance, safener or synergist under Regulation 1107/2009 once the initial approval period has expired or to change the conditions of approval during the approval period;

F27(e) . . . . . .

(f) **[**F28in relation to active substances, safeners or synergists,**]** large data packages in one or more areas of the risk assessment that have been submitted in support of product related applications (e.g. re-registration and new product applications under Regulation 1107/2009) that significantly exceed the size for which the standard fees specified in the product-related application fees table (paragraph 1, items 9a-g above) are payable.

(g) **[**[F28]in relation to active substances, safeners or synergists,**]** additional studies submitted to support an adverse data review.

[[F29](h) in relation to basic substances, resubmissions (for example where the previous application for approval under Regulation 1107/2009 has been unsuccessful and a new application is made in an attempt to address all the concerns raised from that earlier submission);

(i) in relation to basic substances, data to support a change to the conditions of approval of the basic substance.**]**

[[F30]The evaluation of scientific peer reviewed open literature on the active substance or basic substance and its relevant metabolites will be treated as a partial data package.**]**

Textual Amendments

F13 Words in Sch. 1 para. 2 heading substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(a)**; 2020 c. 1, Sch. 5 para. 1(1)

F14 Words in Sch. 1 para. 2 inserted (31.12.2020) by S.I. 2019/720, **Sch. 1 para. 14(3)(b)(i)** (as substituted by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), **Sch. 1 para. 10(4)**)

F15 Words in Sch. 1 para. 2 substituted (31.12.2020) by S.I. 2019/720, **Sch. 1 para. 14(3)(b)(ii)** (as substituted by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), **Sch. 1 para. 10(4)**)

F16 Words in Sch. 1 para. 2 Table heading substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(c)(i)**; 2020 c. 1, Sch. 5 para. 1(1)

F17 Sch. 1 para. 2 Table Item 2 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(c)(ii)**; 2020 c. 1, **Sch. 5 para. 1(1)**

F18 Words in Sch. 1 para. 2 Table Item 3 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(c)(iii)**; 2020 c. 1, **Sch. 5 para. 1(1)**

F19 Words in Sch. 1 para. 2 Table Item 7, 10 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(c)(iv)**; 2020 c. 1, **Sch. 5 para. 1(1)**

F20 Words in Sch. 1 para. 2 Table Item 12 inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(c)(v)**; 2020 c. 1, **Sch. 5 para. 1(1)**

F21 Sch. 1 para. 2 Note 2 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(d)(i)**; 2020 c. 1, Sch. 5 para. 1(1)

F22 Words in Sch. 1 para. 2 Note 3 inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(d)(ii)(aa)**; 2020 c. 1, Sch. 5 para. 1(1)

F23 Words in Sch. 1 para. 2 Note 3 inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(d)(ii)(bb)**; 2020 c. 1, Sch. 5 para. 1(1)

F24 Words in Sch. 1 para. 2 Note 3 inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(d)(ii)(cc)**; 2020 c. 1, Sch. 5 para. 1(1)

F25 Sch. 1 para. 2 Note 4(c) omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(d)(iii)(aa)**; 2020 c. 1, Sch. 5 para. 1(1)

F26 Words in Sch. 1 para. 2 Note 4(d) inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(d)(iii)(bb)**; 2020 c. 1, Sch. 5 para. 1(1)

F27 Sch. 1 para. 2 Note 4(e) omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(d)(iii)(cc)**; 2020 c. 1, **Sch. 5 para. 1(1)**

F28 Words in Sch. 1 para. 2 Note 4(f)(g) inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(d)(iii)(dd)**; 2020 c. 1, Sch. 5 para. 1(1)

F29 Words in Sch. 1 para. 2 Note 4(h)(i) inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(d)(iii)(ee)**; 2020 c. 1, Sch. 5 para. 1(1)

F30 Words in Sch. 1 para. 2 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(3)(d)(iv)**; 2020 c. 1, Sch. 5 para. 1(1)

Fees for official recognition of a test facility or organisation

3. The fees for the official recognition of a test facility or organisation **[**[F31]by a United Kingdom competent authority**]** are in accordance with the following table(1).

Item	*Activity*	*Fee (£)*
1	Initial official recognition of the test facility	2,080
2	Renewal of an official recognition	2,080
3	Each re-inspection	1,560

Notes

(1) Article 29(3) of Regulation 1107/2009 requires that compliance with certain authorisation requirements is established by official or officially recognised tests and analyses.

Textual Amendments

F31 Words in Sch. 1 para. 3 inserted (31.12.2020) by S.I. 2019/720, **Sch. 1 para. 14(3A)** (as inserted by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), **Sch. 1 para. 10(5)**)

Fees related to application for approval of basic substances

[F32]**4.** . . . . . .**]**

Textual Amendments

F32 Sch. 1 para. 4 omitted (31.12.2020) by virtue of The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 14(4)**; 2020 c. 1, Sch. 5 para. 1(1)

[F33SCHEDULE 2

Regulation 4(2)

Import tolerance [F34fees and standalone MRL application fees]

Textual Amendments

F33 Sch. 2 substituted (6.4.2016) by The Plant Protection Products (Fees and Charges) (Amendment) Regulations 2016 (S.I. 2016/254), regs. 1, **2(3)**

F34 Words in Sch. 2 heading substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 15(2)**; 2020 c. 1, Sch. 5 para. 1(1)

[F35Fees for import tolerances]

[F361**].** [F37Fees chargeable by a Great Britain competent authority for import tolerances] are in accordance with the following table.

Item	*Category*	*Fee(£)*
[F38A1	Preliminary consideration of an application to determine whether the application can proceed further	229
A2	Co-ordination of applications	1,872]
1	Full Human health description(1)	16,224
2	Metabolism and residues evaluation(2)	6,760
3	Residues evaluation(3)	2,028

Notes

(1) [F39This category is mainly for active substances not currently approved in respect of the part of Great Britain to which the application relates. In certain cases it may also include active substances still being reviewed if toxicological endpoints have not yet been agreed and accepted in respect of that part of Great Britain.]

(2) This category is for [F40active substances] where toxicological endpoints have already been agreed [F41and accepted in respect of the part of Great Britain to which the application relates], but the residue definition has only been established for crop groups unrelated to the intended use or imported produce.

(3) This category is for [F42active substances] where relevant toxicological endpoints and residue definition have already been agreed [F43and accepted in respect of the part of Great Britain to which the application relates].

[F44Fees for multiple import tolerances for the same active substance are calculated on a modular basis with a charge applied for each crop.]]

Textual Amendments

F35 Sch. 2 para. 1 heading inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 15(3)**; 2020 c. 1, **Sch. 5 para. 1(1)**

F36 Sch. 2 para. 1: Sch. 2 renumbered as Sch. 2 para. 1 (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 15(4)**; 2020 c. 1, **Sch. 5 para. 1(1)**

F37 Words in Sch. 2 para. 1 substituted (31.12.2020) by S.I. 2019/720, **Sch. 1 para. 15(5)(a)** (as substituted by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), **Sch. 1 para. 11(2)(a)**)

F38 Sch. 2 para. 1 Table Item A1, A2 inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 15(5)(b)**; 2020 c. 1, Sch. 5 para. 1(1)

F39 Sch. 2 para. 1 Note 1 substituted by S.I. 2019/720, **Sch. 1 para. 15(5)(c)(i)** (31.12.2020) (as amended by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), **Sch. 1 para. 11(2)(b)(i)**)

F40 Words in Sch. 2 para. 1 Note 2 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 15(5)(c)(ii)(aa)**; 2020 c. 1, Sch. 5 para. 1(1)

F41 Words in Sch. 2 para. 1 Note 2 substituted (31.12.2020) by S.I. 2019/720, reg. 1(2), **Sch. 1 para. 15(5)(c)(ii)(bb)** (as amended by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), **Sch. 1 para. 11(2)(b)(ii)**); 2020 c. 1, **Sch. 5 para. 1(1)**

F42 Words in Sch. 2 para. 1 Note 3 substituted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 15(5)(c)(iii)(aa)**; 2020 c. 1, Sch. 5 para. 1(1)

F43 Words in Sch. 2 para. 1 Note 3 substituted (31.12.2020) by S.I. 2019/720, reg. 1(2), **Sch. 1 para. 15(5)(c)(iii)(bb)** (as amended by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), **Sch. 1 para. 11(2)(b)(ii)**); 2020 c. 1, **Sch. 5 para. 1(1)**

F44 Words in Sch. 2 para. 1 inserted (31.12.2020) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/720), reg. 1(2), **Sch. 1 para. 15(5)(c)(iv)**; 2020 c. 1, Sch. 5 para. 1(1)

[F45Fees for standalone MRL applications

2. Fees chargeable by a Great Britain competent authority for standalone MRL applications are in accordance with the following table.

Item	*Category*	*Fee (£)*
1	Preliminary consideration of an application to determine whether the application can proceed further	229
2	Co-ordination of applications	1,872
3	Full human health description(1)	16,224
4	Metabolism and residues evaluation(2)	6,760
5	Residues evaluation(3)	2,028

Notes

(1) This category is mainly for active substances not currently approved in respect of the part of Great Britain to which the application relates. In certain cases it may also include active substances still being reviewed if toxicological endpoints have not yet been agreed and accepted in respect of that part of Great Britain.

(2) This category is for active substances where toxicological endpoints have already been agreed and accepted in respect of the part of Great Britain to which the application relates but the residue definition has only been established for crop groups unrelated to the intended use.

(3) This category is for active substances where relevant toxicological endpoints and residue definition have already been agreed and accepted in respect of the part of Great Britain to which the application relates.

Fees for multiple standalone applications for the same active substance are calculated on a modular basis with a charge applied for each crop or combination of maximum residue levels.**]**

Textual Amendments

F45 Sch. 2 para. 2 inserted (31.12.2020) by S.I. 2019/720, reg. 1(2), **Sch. 1 para. 15(6)** (as amended by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), **Sch. 1 para. 11(3)(a)(b)**); 2020 c. 1, **Sch. 5 para. 1(1)**

[F46SCHEDULE 3

Regulation 4(2A)

Maximum residue level supplementary information
fees chargeable by a Great Britain competent authority

Textual Amendments

F46 Sch. 3 inserted (31.12.2020) by S.I. 2019/720, reg. 1(2), **Sch. 1 para. 16** (as amended by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), **Sch. 1 para. 12**); 2020 c. 1, **Sch. 5 para. 1(1)**

Fees chargeable by a Great Britain competent authority for the evaluation of supplementary information provided in accordance with Article 14(3) of the MRL Regulation are in accordance with the following table.

Item	*Category*	*Fee (£)*
1	Preliminary consideration of application to determine whether the application can proceed further	229
2	Co-ordination of applications	1,872
3	Simple reasoned case(1)	416
4	Analytical method(2)	416
5	Toxicology(3)	3,120

6	Metabolism and residues evaluation(4)	6,760
7	Residues evaluation(5)	2,028

Notes

(1) This category is for an MRL supplementary information requirement to provide additional information on aspects of the data already evaluated or to provide evidence of the commercial availability of standards for MRL compliance.

(2) This category is for an MRL supplementary information requirement to provide an analytical method for MRL compliance.

(3) This category is for an MRL supplementary information requirement to address the toxicological relevance of a metabolite identified in plants or products of animal origin.

(4) This category is for an MRL supplementary information requirement to address plant or livestock metabolism or any other nature of residue study.

(5) This category is for an MRL supplementary information requirement to provide additional residue trials or any other magnitude of residue study including monitoring data.

Fees for multiple submissions to address MRL supplementary information for the same active substance are calculated on a modular basis with a charge applied for each MRL supplementary information requirement. Large or novel studies to address MRL supplementary information requirements will incur an additional fee, as a multiple of the original fee, if significant extra work is required over and above the usual level for the module in question.**]**

Changes to legislation:
There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Plant Protection Products (Fees and Charges) Regulations 2011. Any changes that have already been made by the team appear in the content and are referenced with annotations.
View outstanding changes

Changes and effects yet to be applied to :

- Sch. 1 para. 2 words substituted by S.I. 2019/720 Sch. 1 para. 14(3)(b) (This amendment not applied to legislation.gov.uk. Sch. 1 para. 14(3)(b) substituted immediately before IP completion day by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 10(4))
- Sch. 2 para. 1 words substituted by S.I. 2019/720 Sch. 1 para. 15(5)(a) (This amendment not applied to legislation.gov.uk. Sch. 1 para. 15(5)(a) substituted immediately before IP completion day by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 11(2)(a))
- reg. 2 words substituted by S.I. 2022/1037 reg. 12(2)
- reg. 3 omitted by S.I. 2019/720 Sch. 1 para. 9 (This amendment not applied to legislation.gov.uk. Sch. 1 para. 9 substituted immediately before IP completion day by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 6)
- reg. 4(2) words inserted by S.I. 2019/720 Sch. 1 para. 10(2) (This amendment not applied to legislation.gov.uk. Sch. 1 para. 10 substituted immediately before IP completion day by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 7)
- reg. 8(6) word omitted by S.I. 2019/720 Sch. 1 para. 13(a) (This amendment not applied to legislation.gov.uk. Sch. 1 para. 13 substituted immediately before IP completion day by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 9)
- reg. 8(6) words inserted by S.I. 2019/720 Sch. 1 para. 13(b)

Changes and effects yet to be applied to the whole Instrument associated Parts and Chapters:
Whole provisions yet to be inserted into this Instrument (including any effects on those provisions):

- reg. 4(2A) inserted by S.I. 2019/720 Sch. 1 para. 10(3) (This amendment not applied to legislation.gov.uk. Sch. 1 para. 10 substituted immediately before IP completion day by S.I. 2020/1567, reg. 1(2), Sch. 1 para. 7)